Becton, Dickinson And Co.

Most Recent

  • uploads///Chart  NMDA
    Company & Industry Overviews

    What Are Sage Therapeutics’ Receptor-Based Products?

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///AXDX analysts Reco
    Company & Industry Overviews

    What Analysts Recommend for Accelerate Diagnostics and Peers

    Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///projections
    Earnings Report

    Becton, Dickinson and Company’s 4Q16 Earnings Estimates

    Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Will Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18?

    In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.

    By Sarah Collins
  • uploads///REVENUE ESTIMATES
    Earnings Report

    Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17

    Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    How Has Medtronic’s Stock Performed Recently?

    Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Medtronic’s Revenue Is Estimated to Rise in Fiscal 2Q17

    On November 22, 2016, Medtronic (MDT) will announce its fiscal 2Q17 earnings for the period that ended on October 31, 2016.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    BD’s Stock Price Performance after Recent 52-Week High

    On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?

    For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Abbott Laboratories’ Stock Performance after a Recent Bull Run

    On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Company & Industry Overviews

    Trade War Fears Triggered Medtronic’s Stock Decline on March 23

    Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Has Boston Scientific Stock Performed Recently?

    Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

    By Sarah Collins
  • uploads///laboratory _
    Earnings Report

    Becton Dickinson Reports 2Q18 Earnings Results

    Today, Becton, Dickinson and Company (BDX), or BD, released its 1Q18 earnings results for the quarter that ended on March 31.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Baxter Exhibits Strong 1Q16 Performance, Beat Estimates

    On April 26, 2016, Baxter International (BAX) released its 1Q16 earnings. After the announcement, Baxter’s share price rose ~1% from $43.63 on April 25, 2016, due to the company’s better-than-expected 1Q16 results.

    By Sarah Collins
  • uploads///revenue estimates
    Company & Industry Overviews

    Stryker’s Recent Stock Price Movement: Upside Potential?

    Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    A Look at Medtronic’s Recent Stock Performance

    Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.

    By Sarah Collins
  • uploads///COMPLEMENTARY PORTFOLIO
    Company & Industry Overviews

    Effect of Claris Injectables Acquisition on Baxter’s 2017 Growth

    On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    Wall Street Maintains ‘Strong Buy’ Recommendation for Stryker

    Analysts’ recommendations Stryker (SYK) has registered strong results over the last few quarters and has been expanding at a fast pace through organic and inorganic growth. The company has made a number of acquisitions and expanded its market presence across product lines and regions. Its most recent earnings results were reported on October 26, 2017. For details, read […]

    By Sarah Collins
  • uploads///geographic strength
    Company & Industry Overviews

    How BD-Bard Acquisition Will Strengthen International Presence

    C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.

    By Sarah Collins
  • uploads///key strategies
    Company & Industry Overviews

    Understanding Zimmer Biomet’s Latest Dividend Announcement

    On December 18, 2017, Zimmer Biomet Holdings (ZBH) announced a quarterly cash dividend of $0.24 per share for fiscal 4Q17.

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    What Can We Expect for Stryker’s Earnings in 2Q16?

    In 1Q16, Stryker exceeded analysts’ EPS (earnings per share) estimate of $1.20, as well as the revenue estimate of ~$2.5 billion.

    By Sarah Collins
  • uploads///analysis _
    Company & Industry Overviews

    How Wall Street Analysts View Medtronic in December

    Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Thermo Fisher’s Third-Quarter Revenue Estimates

    The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.

    By Mike Benson
  • uploads///TMO drivres
    Company & Industry Overviews

    What’s Driving the Growth in Thermo Fisher Scientific’s Segments?

    Thermo Fisher Scientific (TMO) operates in four business segments.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for DaVita on September 17

    Analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

    By Mike Benson
  • uploads///chemist _
    Company & Industry Overviews

    How Thermo Fisher Scientific’s Valuation Looks in September

    Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.

    By Mike Benson
  • uploads///TFX
    Company & Industry Overviews

    Analysts Still Bullish on Teleflex Stock

    Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///analysis _
    Company & Industry Overviews

    How Analysts View Becton Dickinson in August 2018

    On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65.

    By Daniel Collins
  • uploads///medic _
    Earnings Report

    Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates

    Haemonetics reported an 8.7% YoY increase in revenues to $229.3 million during Q1 2019 as compared to revenues of $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///mammography _
    Company & Industry Overviews

    Analysts’ Recommendations for Hologic and Its Peers in August

    Of the 19 analysts covering Hologic (HOLX) in August, five rated it as a “strong buy,” and seven rated it as a “buy.”

    By Margaret Patrick
  • uploads///health _
    Company & Industry Overviews

    Analyst Recommendations for Boston Scientific and Peers in June

    Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///computer _
    Company & Industry Overviews

    How Much Upside Do Analysts See in Baxter Stock?

    Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?

    Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BAX May See Slight Rise in Net Profit Margins in Fiscal 2018

    In 4Q17, Baxter International (BAX) reported adjusted earnings per share close to $0.64, which represents year-over-year growth of 12.0%.

    By Margaret Patrick
  • uploads///daniel frank  unsplash
    Company & Industry Overviews

    Analysts’ March 2018 Ratings for Baxter International and Peers

    In March, 17 analysts tracked Baxter International. Three gave a “strong buy” rating, seven gave a “buy” rating, and six suggested a “hold.”

    By Margaret Patrick
  • uploads///recommendations
    Earnings Report

    What Analysts Recommend for Medtronic ahead of 3Q18 Earnings

    Medtronic (MDT) plans to release its 3Q18 earnings results on February 20, 2018.

    By Sarah Collins
  • uploads///ambulance _
    Earnings Report

    BDX’s New Reporting Structure after Bard Acquisition

    Becton, Dickinson and Company (BDX) completed the acquisition of Bard on January 29, 2018.

    By Sarah Collins
  • uploads///conclusion of the contract __
    Company & Industry Overviews

    How BD Stock Has Performed in the Last Year

    On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations.

    By Sarah Collins
  • uploads///ambulance _
    Earnings Report

    BD Medical Segment Posted Strong Fiscal 1Q18 Performance

    In fiscal 1Q18, BDX’s Medication and Procedural Solutions business registered sales growth of 5.0%.

    By Sarah Collins
  • uploads///DEAL RATIONALE
    Company & Industry Overviews

    Rationale behind Varian Medical’s Acquisition of Sirtex Medical

    On January 30, 2018, Varian Medical Systems (VAR) announced that it had entered into an agreement to acquire Sirtex Medical Limited for $1.3 billion.

    By Sarah Collins
  • uploads///EARNINGS ESTIMATES
    Earnings Report

    Will ZBH Beat Wall Street Earnings Estimates in 4Q17?

    Zimmer Biomet Holdings (ZBH) accounts for ~0.17% of the total holdings of the Vanguard International High Dividend Yield ETF (VYMI). Zimmer Biomet Holdings plans to announce its 4Q17 and fiscal 2017 earnings results on January 30.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results

    Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.

    By Sarah Collins
  • uploads///AXDX RD Expenses
    Company & Industry Overviews

    What Are Accelerate Diagnostics’ Key Strengths?

    In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.

    By Kenneth Smith
  • uploads///AXDX revenue growth
    Company & Industry Overviews

    Does Accelerate Diagnostics’ Financial Performance Bode Well?

    The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.

    By Kenneth Smith
  • uploads///stock price
    Company & Industry Overviews

    Stryker’s Stock Rally Continues with 52-Week High Yesterday

    On January 9, Stryker (SYK) traded at a 52-week high of $164.2 per share. The stock ended trading with a closing price of $160.4.

    By Sarah Collins
  • uploads///free cash flow
    Company & Industry Overviews

    What’s Driving Baxter International’s Cash Flow Growth

    Baxter International’s 2017 cash flow Between 9M16 (the first nine months of 2016) and 9M17, Baxter International’s (BAX) cash flow rose by $514 million to $933 million, exceeding its cash flow of $905 million in fiscal 2016. In fiscal 9M17, Baxter had operating cash flow of ~$1.3 billion, up $405 million from fiscal 9M16. In fiscal 2017, Baxter expects to […]

    By Sarah Collins
  • uploads///dispensing business model change
    Company & Industry Overviews

    BD Advances Medication Management Business through Innovations

    Becton, Dickinson and Company (BDX), or BD, established itself as the leader in the medication management market with the acquisition of CareFusion in 2015.

    By Sarah Collins
  • uploads///GOP TAX BILL
    Healthcare

    How the Corporate Tax Rate Cut Could Affect R&D in the Medtech Industry

    The repeal of the tax deduction for high medical expenses may reduce the number of taxpayers opting for costly medical technologies and services.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018

    In fiscal 2018, Myriad Genetics (MYGN) expects to witness rapid expansion in reimbursement for GeneSight based on positive results of the 1,200-patient pharmacogenomic study.

    By Margaret Patrick
  • uploads///objectives
    Company & Industry Overviews

    A Look at Varian Medical Systems’ Long-Term Objectives

    Varian Medical Systems (VAR) spun off its imaging components business into Varex Imaging in January 2017, thus strengthening its positioning in the oncology market.

    By Sarah Collins
  • uploads///FREE CASH FLOWS
    Company & Industry Overviews

    The Free Cash Flow Estimates of Medtronic in 2018 and Beyond

    In fiscal 2Q18, Medtronic used a portion of its divestiture proceeds toward stock buybacks. The total share repurchases in the quarter came in at ~$568.0 million.

    By Sarah Collins
  • uploads///EMERGING MARKET OPORTUNITY
    Company & Industry Overviews

    Emerging Markets Growth Is Driving Medtronic’s Geographic Strategy

    In fiscal 2Q18, Medtronic registered sales of ~$1.1 billion from emerging markets.

    By Sarah Collins
  • uploads///operatingmargin
    Company & Industry Overviews

    What’s Driving BD’s Operating Margin Expansion

    Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]

    By Sarah Collins
  • uploads///EMERGING MARKET PERFORMANCE
    Company & Industry Overviews

    How Emerging Markets Continue to be the Key Growth Driver for BD

    Overview BD (BDX) has significantly diversified operations around the world. It has a diverse base in emerging markets such as Eastern Europe, Latin America, Africa, the Middle East, and certain Asia-Pacific countries. The company is focused on expanding its operations in these high-growth markets and is undertaking strategic initiatives in this regard. It is mainly focused […]

    By Sarah Collins
  • uploads///medical device segment performance
    Company & Industry Overviews

    How JNJ’s Medical Devices Business Restructuring Efforts Are Panning Out

    In 3Q17, Johnson & Johnson (JNJ) reported ~$19.7 billion in sales. The company’s Medical Devices business generated ~33.5% of the total sales.

    By Sarah Collins
  • uploads///OPERATIONAL PLANS
    Company & Industry Overviews

    Zimmer Biomet’s Plan to Revive Growth amid Supply Disruptions

    Zimmer Biomet Holdings has laid down a dual sourcing strategy to resolve production issues at its Warsaw facility.

    By Sarah Collins
  • uploads///guidance
    Company & Industry Overviews

    Baxter International’s Latest Guidance for Fiscal 2017

    Baxter International’s sales growth guidance for fiscal 2017 is expected to be ~4% on a reported basis.

    By Sarah Collins
  • uploads///da vinci x
    Company & Industry Overviews

    How Intuitive Surgical Is Expanding Its Da Vinci X Systems Worldwide

    Intuitive Surgical’s (ISRG) Da Vinci X received early FDA approval in May 2017 and was given a CE Mark in Europe in April 2017.

    By Sarah Collins
  • uploads///medical pipeline
    Company & Industry Overviews

    What’s BD’s Latest News in the Diabetes Management Market?

    On September 19, 2017, Becton, Dickinson, and Company (BDX), or BD, introduced a new pen needle for its pen injection devices.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Understanding BD’s Recent Stock Performance

    BD has a 50-day moving average of $197.25, while its 200-day moving average is $192.35.

    By Sarah Collins
  • uploads///faster growth markets
    Company & Industry Overviews

    How Boston Scientific Plans to Expand in High-Growth Markets

    Boston Scientific is focused on accelerating the company’s growth by expanding across high-growth markets outside the United States.

    By Sarah Collins
  • uploads///DIVIDEND HISTORY
    Company & Industry Overviews

    Abbott Laboratories’ 375th Consecutive Quarterly Dividend

    On September 14, 2017, Abbott Laboratories (ABT) announced its 375th consecutive quarterly dividend to be paid on November 15, 2017.

    By Sarah Collins
  • uploads///life sciences strategy
    Company & Industry Overviews

    Latest Product Launch Expands BD’s Genomics Portfolio

    Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.

    By Sarah Collins
  • uploads///pipeline
    Company & Industry Overviews

    Medtronic’s Robust Product Pipeline

    On May 1, 2017, Medtronic announced the FDA approval of its Resolute Onyx DES (drug eluting stent) for adult patients suffering from coronary artery disease.

    By Sarah Collins
  • uploads///margin
    Company & Industry Overviews

    What’s behind Medtronic’s Accelerating Margin Expansion?

    In fiscal 1Q18, Medtronic (MDT) reported ~26.9% of operating margin on a constant currency basis. This represented year-over-year growth of ~50 basis points.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Taking a Look at Stryker’s Recent Stock Price Performance

    On August 31, Stryker (SYK) closed trading at a closing price of $139.3. It has a 50-day moving average of $144.7 and a 200-day moving average of $137.5.

    By Sarah Collins
  • uploads///covidien synergies
    Company & Industry Overviews

    How Medtronic Is Delivering on Its Covidien Synergies

    In January 2015, Medtronic (MDT) acquired Covidien for ~$43 billion in cash and MDT stock in a tax inversion deal.

    By Sarah Collins
  • uploads///EMERGING MARKET OPORTUNITY
    Company & Industry Overviews

    Medtronic’s Emerging Market Position and Opportunities for Fiscal 2018

    Medtronic (MDT) registered revenues of ~$1.0 billion revenues from emerging markets in fiscal 1Q18, which represents YoY (year-over-year) sales growth of ~11% in that market.

    By Sarah Collins
  • uploads///results
    Company & Industry Overviews

    Did June’s IT Disruption Hurt Medtronic’s Sales in Fiscal 1Q18?

    On June 19, 2017, Medtronic (MDT) experienced a global technology glitch, which led to IT disruption throughout the company.

    By Sarah Collins
  • uploads///EMERGING MARKET PERFORMANCE
    Company & Industry Overviews

    How Is Becton Dickinson Progressing with Emerging Market Growth?

    Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.

    By Sarah Collins
  • uploads///dispensing business model change
    Company & Industry Overviews

    Headwind for Becton Dickinson: US Dispensing Business

    Becton Dickinson (BDX) is the leading player in the US dispensing business. Its Pyxis system sales contribute significantly to the company’s total revenues.

    By Sarah Collins
  • uploads///PROTON THERAPY
    Company & Industry Overviews

    How Varian Is Harnessing Proton Therapy Market Opportunities

    Proton therapy market opportunities The proton therapy market is a highly lucrative opportunity area for Varian Medical Systems (VAR). Proton therapy uses protons for treating cancer instead of X-rays. According to a Medgadget report, the global proton therapy market is expected to double by the year 2022. Though the United States has the biggest proton […]

    By Sarah Collins
  • uploads///STOCK
    Earnings Report

    Key Drivers behind BDX’s Recent Stock Performance

    BDX has a 50-day moving average of $196.80 and a 200-day moving average of $185.70.

    By Sarah Collins
  • uploads///stock price
    Earnings Report

    How Thermo Fisher Scientific’s Stock Has Performed

    Thermo Fisher Scientific (TMO) closed trading at $175.3 on July 27, 2017.

    By Sarah Collins
  • uploads///capital allocation
    Earnings Report

    How BDX Returns Value to Its Shareholders

    BD announced a quarterly cash dividend of $0.73 per share on July 25, 2017.

    By Sarah Collins
  • uploads///RECOMMENDATIONS
    Company & Industry Overviews

    Most Analysts Recommend ‘Buys’ on Thermo Fisher Scientific

    In a recent Reuters survey of 17 brokerage companies, Thermo Fisher Scientific received “buy” ratings from ~88% of analysts, while ~12% gave it “hold” ratings.

    By Sarah Collins
  • uploads///STOCK
    Company & Industry Overviews

    Behind BD’s Recent New Stock Price High

    BD (BDX) closed trading at $195.3 on July 6, 2017, ahead of its 50-day moving average of $191.3 and its 200-day moving average of $181.9.

    By Sarah Collins
  • uploads///growth drivers
    Company & Industry Overviews

    FDA Warning Letter to Zimmer Biomet Resolved, Boosts Confidence

    On June 13, 2017, Zimmer Biomet (ZBH) announced that the FDA warning letter issued in June 2015 relating to its Zhejiang manufacturing facility in China has been closed.

    By Sarah Collins
  • uploads///ASTHMA
    Company & Industry Overviews

    How Boston Scientific’s Alair System Performed in Trials

    Boston Scientific’s Alair Bronchial Thermoplasty System is used to treat patients suffering from severe asthma.

    By Sarah Collins
  • uploads///geographic segmentationn
    Company & Industry Overviews

    How Stryker Plans to Capture the International Markets

    Most of Stryker’s emerging market sales are from China. However, Europe and emerging markets sales have witnessed high growth in recent quarters.

    By Sarah Collins
  • uploads///stock
    Company & Industry Overviews

    Behind Thermo Fisher’s Recent Stock Performance

    TMO stock was trading at $173.2 on May 30, 2017. The stock had a 50-day moving average of $165.9 and a 200-day moving average of $153.8 that day.

    By Sarah Collins
  • uploads///strategic initiatives
    Company & Industry Overviews

    Behind BD’s Recent Strategic Initiatives and Product Launches

    In its diabetes business, BD (BDX) is working with Medtronic (MDT) to relaunch a new infusion set, after the temporary suspension of its shipments.

    By Sarah Collins
  • uploads///CHART
    Macroeconomic Analysis

    Trump Trade Fades amid Political Debacle: What’s the Impact?

    As part of Obamacare, a medical device tax of 2.3% has been implemented on medical device companies in the United States.

    By Sarah Collins
  • uploads///DEAL RATIONALE
    Company & Industry Overviews

    A Look at BD’s Deal Rationale in Its C.R. Bard Acquisition

    BD’s acquisition of C.R. Bard is aimed at providing a comprehensive product portfolio to customers at more reasonable costs and enhanced efficiency.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Changes in Bristol-Myers Squibb’s Profitability in 2016

    Bristol-Myers Squibb (BMY) reported a rise of 17% in revenue to ~$19.4 billion in 2016, compared to $16.6 billion in 2015. The company reported a net profit of ~$4.5 million in 2016.

    By Mike Benson
  • uploads///FY GUIDANCE
    Company & Industry Overviews

    Inside Becton Dickinson’s Financial Guidance for 2017

    Becton, Dickinson and Company (BDX), expects its 2017 sales to be hit due to the divestiture of its Respiratory Solutions business, which was completed in October 2016.

    By Sarah Collins
  • uploads///medical pipeline
    Company & Industry Overviews

    Analyzing the BD Medical Segment’s Product Pipeline

    Becton, Dickinson and Company (BDX) generates ~$1 billion from its Infection Prevention business.

    By Sarah Collins
  • uploads///be medical
    Company & Industry Overviews

    BD’s Medical Segment Performance and Growth Strategy

    The BD Medical business generated revenues of ~$8.7 billion in fiscal 2016, which ended September 30, 2016.

    By Sarah Collins
  • uploads///LIFESCIENCES PIPELINE
    Company & Industry Overviews

    BD Lifesciences’s Product Pipeline Could Boost Its Fiscal 2017 Growth

    Becton, Dickinson and Company (BDX) recently launched BD Barricor and BD Ultra Touch Push Button under its Pre-Analytical Systems division.

    By Sarah Collins
  • uploads///GROWTH
    Company & Industry Overviews

    Becton Dickinson’s Long-Term Growth Profile and Expectations

    After executing its growth strategies during the last five years, Becton, Dickinson and Company (BDX) has achieved its targeted growth rates of 5% top-line organic growth and 10% bottom-line growth.

    By Sarah Collins
  • uploads///capital allocaton
    Company & Industry Overviews

    Baxter’s Latest Dividend and Share Repurchase Authorization

    Baxter International (BAX) announced a quarterly cash dividend of $0.13 per share on November 8, 2016.

    By Sarah Collins
  • uploads///global footprint
    Company & Industry Overviews

    BD’s Diversified Geographic Footprints: What Will Drive Growth?

    Becton Dickinson (BDX) has a diversified presence around the world. The company’s sales contribution in 2016 from the United States, however, rose to 55% from around 50% in 2015.

    By Sarah Collins
  • uploads///STOCK
    Earnings Report

    How Did Stryker’s Stock Perform after Its 3Q Earnings Release?

    Stryker (SYK) was trading at $114.30 on October 28, 2016, with a 50-day moving average of $114.70 and a 200-day moving average of $114.60.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    Analyzing Johnson & Johnson’s Recent Stock Performance

    Johnson & Johnson (JNJ) was trading at $114.90 on October 20, 2016, with a 50-day moving average of $118.40 and a 200-day moving average of $117.60.

    By Sarah Collins
  • uploads///medical device segment
    Earnings Report

    Medical Devices Revive JNJ’s Revenue Performance

    In 3Q16, Johnson & Johnson’s (JNJ) Medical Device segment revenues came in at ~$6.2 billion, compared to $6.1 billion in 3Q15.

    By Sarah Collins
  • uploads///emerging markets
    Company & Industry Overviews

    TMO Focused on Strengthening Its Emerging Market Presence

    Thermo Fisher Scientific (TMO) has grown in double digits in China, which is now the company’s second-largest market by geography.

    By Sarah Collins
  • uploads///performance
    Company & Industry Overviews

    Baxter International’s Recent Product Launches and Partnerships

    Baxter International’s R&D investments were around $150 million in 2Q16, which represents a YoY (year-over-year) increase of around 1%.

    By Sarah Collins
  • uploads///STRYKER  ACQUISITIONS
    Company & Industry Overviews

    Stryker Acquires Ivy Sports Medicine to Strengthen Its Business

    On September 1, Stryker (SYK) announced the acquisition of Ivy Sports Medicine. It’s the latest acquisition by Stryker so far in 2016.

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    Latest Analyst Recommendations for Johnson & Johnson

    In this part of the series, we’ll look at Wall Street analysts’ recommendations and target prices for Johnson & Johnson’s (JNJ) stock over the next 12 months.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.